GH Research (GHRS) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
GH Research (GHRS) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 60.2% versus a gain of 4.9%. Over five years, GHRS leads with a +24.2% price change compared with -8.6% for SNDX. Syndax Pharmaceuticals is the larger company by market cap ($1.52 billion vs $1.45 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | SNDX |
|---|---|---|
| Share price | $21.11 | $16.99 |
| Market cap | $1.45B | $1.52B |
| 1-day change | +3.23% | +0.53% |
| YTD return | +66.22% | -19.13% |
| 1-year return | +60.17% | +4.88% |
| 5-year return | +24.18% | -8.61% |
| EPS (TTM) | $-0.99 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | — | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $31.44 | $25.59 |
| 52-week low | $12.04 | $12.99 |
| Distance from 52-week high | -32.85% | -33.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +103.17% | +121.01% |
| Average volume | 294.29K | 1.54M |
| Shares outstanding | 68.64M | 89.30M |
| Employees | 73 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed SNDX by 55.3 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
GHRS vs SNDX FAQ
Which is bigger, GH Research or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $1.52B compared with $1.45B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or SNDX?
GHRS returned +60.17% over the past 12 months, compared with +4.88% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.